Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced Efficacy of EGFR-Targeted ADCs via p38-Mediated Noncanonical Endocytosis in EGFR-Mutant Lung Cancer Cells.

Biological & pharmaceutical bulletin - 1 Jan 2026

Otsuyama Kyoko, Morita Shinya, Sato Maki, Zhou Yue, Yokoyama Satoru, Azuma Koichi, Kato Yukinari, Hayashi Ryuji, Sakurai Hiroaki

Abstract excerpt

Antibody-drug conjugates (ADCs) have revolutionized targeted cancer therapy, with human epidermal growth factor receptor 2-targeted ADCs demonstrating notable clinical success. In contrast, the clinical efficacy of epidermal growth factor receptor (EGFR)-targeted ADCs has not yet been clearly demonstrated, owing to several underlying factors. In this study, we focused on one of the key determinants most directly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Cisplatin

Share to Endocytosis

Share to ErbB Receptors

Share to Immunoconjugates

Share to p38 Mitogen-Activated Protein Kinases

Source

Identifiers

PMID: 42252196
DOI: 10.1248/bpb.b26-00027

Genes

EGFR
PC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced Efficacy of EGFR-Targeted ADCs via p38-Mediated Noncanonical Endocytosis in EGFR-Mutant Lung Cancer Cells.PMID 42252196Read ↗

Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.Semantic proximity Read ↗

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.Semantic proximity Read ↗

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLCSemantic proximity Read ↗

Toward targeting the untargetable: A non-canonical EGFR-peptide-drug conjugate achieves potent antitumor activity in KRAS-mutant CRC.Semantic proximity Read ↗

Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.Semantic proximity Read ↗

EGFR mutations and abnormal trafficking in cancers.Semantic proximity Read ↗

Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutantsSemantic proximity Read ↗

Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.Semantic proximity Read ↗

Cancer Selective Target Degradation by Folate-Caged PROTACsSemantic proximity Read ↗

Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants.Semantic proximity Read ↗

Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.